Trials / Completed
CompletedNCT00475644
A Study of Enzastaurin in Participants With Follicular Lymphoma
A Phase 2 Study of Enzastaurin in Participants With Follicular Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the antitumor activity, as measured by tumor response rate, of enzastaurin in participants with Follicular Lymphoma (FL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enzastaurin | Administered orally |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2012-04-01
- Completion
- 2014-12-01
- First posted
- 2007-05-21
- Last updated
- 2018-11-05
- Results posted
- 2018-11-05
Locations
23 sites across 2 countries: United States, Germany
Source: ClinicalTrials.gov record NCT00475644. Inclusion in this directory is not an endorsement.